Since 2020, the combination of atezolizumab and bevacizumab (AB), comprising an anti-PD-L1 antibody and an anti-vascular endothelial growth factor antibody, has emerged as a frontline standard systemic treatment for advanced HCC, improving survival outcomes compared with prior therapies. The gene discussed is CD274; the disease is hepatocellular carcinoma.